Rallybio Corporation (RLYB)
Market Open
11 Sep, 14:04
NASDAQ (NGS) NASDAQ (NGS) Primary $
16. 92
+0.17
+1.0149%
$
88.15M Market Cap
- P/E Ratio
- Div Yield
683 Volume
-1.55 Eps
$ 16.75
Previous Close Investors:
Want to track RLYB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Seekingalpha | 3 months ago
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Seekingalpha | 6 months ago
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Zacks | 1 year ago
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 2 years ago
